ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P31-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Thrombopoietin Receptor Agents
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 05, 2017
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2701 - 2710 လၢ 4233 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P57-17 Addition of Drugs to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 24, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P39-17 Concurrent Review for Inpatient Hospital Services at Select Facilities
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 11, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P62-16 EY Modifier for Platinum Blue Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 13, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P32-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Kuvan
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P42-16 Change in Medical Policy and Commercial Benefit Coverage of Cologuard Colorectal Cancer Screening Test
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 08, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P1-17 Prior Authorization Requirement for Gender Dysphoria
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 18, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P44-16 Addition of a Drug (Viekira XR) to the Hepatitis C Second Generation Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 01, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P47-17 Change to the Requirement to Submit National Drug Codes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 23, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P36-16 Case Management (T1016) Billing for Tuberculosis Related Services for Government Programs Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2016